Arizona State Retirement System decreased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 7.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 21,936 shares of the company's stock after selling 1,795 shares during the quarter. Arizona State Retirement System's holdings in IDEXX Laboratories were worth $14,840,000 as of its most recent SEC filing.
A number of other hedge funds also recently bought and sold shares of IDXX. Bank of New York Mellon Corp grew its holdings in IDEXX Laboratories by 41.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 2,056,680 shares of the company's stock worth $1,313,992,000 after acquiring an additional 605,290 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in IDEXX Laboratories by 60.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 869,930 shares of the company's stock worth $555,802,000 after acquiring an additional 326,348 shares in the last quarter. Zurich Insurance Group Ltd FI purchased a new stake in shares of IDEXX Laboratories during the third quarter valued at about $143,730,000. Principal Financial Group Inc. lifted its position in shares of IDEXX Laboratories by 16.7% during the third quarter. Principal Financial Group Inc. now owns 1,315,722 shares of the company's stock valued at $840,638,000 after buying an additional 187,967 shares during the last quarter. Finally, Invesco Ltd. lifted its position in shares of IDEXX Laboratories by 14.0% during the third quarter. Invesco Ltd. now owns 1,320,263 shares of the company's stock valued at $843,503,000 after buying an additional 161,782 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.
IDEXX Laboratories Price Performance
NASDAQ:IDXX opened at $565.93 on Friday. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.90. The firm has a market cap of $44.95 billion, a price-to-earnings ratio of 43.30, a price-to-earnings-growth ratio of 3.41 and a beta of 1.72. The company has a 50 day moving average price of $594.81 and a 200-day moving average price of $652.81. IDEXX Laboratories, Inc. has a 1-year low of $427.70 and a 1-year high of $769.98.
IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its earnings results on Monday, February 2nd. The company reported $3.08 earnings per share for the quarter, beating the consensus estimate of $2.93 by $0.15. The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The business's quarterly revenue was up 14.3% on a year-over-year basis. During the same period in the previous year, the firm earned $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Equities research analysts forecast that IDEXX Laboratories, Inc. will post 14.54 EPS for the current year.
Analyst Ratings Changes
Several analysts have commented on the stock. UBS Group decreased their price target on shares of IDEXX Laboratories from $750.00 to $730.00 and set a "neutral" rating for the company in a research report on Tuesday, February 3rd. Wall Street Zen lowered shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Saturday. Stifel Nicolaus decreased their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a "buy" rating for the company in a research report on Tuesday, March 31st. Piper Sandler decreased their price target on shares of IDEXX Laboratories from $775.00 to $750.00 and set a "neutral" rating for the company in a research report on Monday, February 9th. Finally, BTIG Research decreased their price target on shares of IDEXX Laboratories from $830.00 to $800.00 and set a "buy" rating for the company in a research report on Tuesday, February 3rd. Seven investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, IDEXX Laboratories currently has a consensus rating of "Moderate Buy" and an average price target of $760.00.
Check Out Our Latest Stock Report on IDXX
Insider Buying and Selling
In other IDEXX Laboratories news, CEO Jonathan Jay Mazelsky sold 23,326 shares of IDEXX Laboratories stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $657.55, for a total transaction of $15,338,011.30. Following the sale, the chief executive officer owned 83,606 shares of the company's stock, valued at $54,975,125.30. The trade was a 21.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Sophie V. Vandebroek sold 1,464 shares of IDEXX Laboratories stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $628.62, for a total transaction of $920,299.68. Following the sale, the director directly owned 648 shares in the company, valued at approximately $407,345.76. This trade represents a 69.32% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 45,957 shares of company stock worth $29,862,109 in the last 90 days. 0.79% of the stock is owned by insiders.
IDEXX Laboratories Profile
(
Free Report)
IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.
IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider IDEXX Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.
While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
